Marie Thibault
Stock Analyst at BTIG
(4.07)
# 553
Out of 4,996 analysts
80
Total ratings
55.41%
Success rate
12.37%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Reiterates: Buy | $127 | $98.18 | +29.35% | 11 | Sep 23, 2025 | |
| MASI Masimo | Reiterates: Buy | $198 | $141.48 | +39.95% | 4 | Sep 11, 2025 | |
| EMBC Embecta | Reiterates: Buy | $25 | $13.90 | +79.86% | 3 | Sep 5, 2025 | |
| OBIO Orchestra BioMed Holdings | Downgrades: Neutral | n/a | $2.40 | - | 2 | Aug 20, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $148 → $145 | $133.55 | +8.57% | 12 | Jul 18, 2025 | |
| ATRC AtriCure | Maintains: Buy | $58 → $52 | $35.17 | +47.85% | 7 | Apr 30, 2025 | |
| PODD Insulet | Maintains: Buy | $260 → $270 | $318.00 | -15.09% | 4 | Nov 8, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $39.11 | +66.20% | 8 | Oct 14, 2024 | |
| HAE Haemonetics | Initiates: Buy | $112 | $48.17 | +132.51% | 1 | Sep 10, 2024 | |
| DXCM DexCom | Maintains: Buy | $156 → $120 | $67.10 | +78.84% | 7 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.46 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.32 | - | 3 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $20 | $10.75 | +86.13% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $170.81 | -18.04% | 7 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $1.67 | +319.16% | 1 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.71 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.46 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $292.76 | -97.95% | 1 | Apr 9, 2020 |
Boston Scientific
Sep 23, 2025
Reiterates: Buy
Price Target: $127
Current: $98.18
Upside: +29.35%
Masimo
Sep 11, 2025
Reiterates: Buy
Price Target: $198
Current: $141.48
Upside: +39.95%
Embecta
Sep 5, 2025
Reiterates: Buy
Price Target: $25
Current: $13.90
Upside: +79.86%
Orchestra BioMed Holdings
Aug 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.40
Upside: -
Abbott Laboratories
Jul 18, 2025
Maintains: Buy
Price Target: $148 → $145
Current: $133.55
Upside: +8.57%
AtriCure
Apr 30, 2025
Maintains: Buy
Price Target: $58 → $52
Current: $35.17
Upside: +47.85%
Insulet
Nov 8, 2024
Maintains: Buy
Price Target: $260 → $270
Current: $318.00
Upside: -15.09%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $39.11
Upside: +66.20%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $48.17
Upside: +132.51%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $67.10
Upside: +78.84%
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.46
Upside: -
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.32
Upside: -
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $10.75
Upside: +86.13%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $170.81
Upside: -18.04%
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $1.67
Upside: +319.16%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $2.71
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.46
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $292.76
Upside: -97.95%